Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.

Allergy - 1 Jul 2012

Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl W F, Willmann M, Valent P

Abstract excerpt

BACKGROUND: Advanced mast cell (MC) disorders are characterized by uncontrolled growth of neoplastic MC in various organs, mediator-related symptoms, and a poor prognosis. Kit mutations supposedly contribute to abnormal growth and drug resistance in these patients. METHODS: We established a novel canine mastocytoma cell line, NI-1, from a patient suffering from MC leukemia. RESULTS: NI-1 cells were found to form...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 3
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Mast Cells

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Proto-Oncogene Proteins c-kit

Share to Receptors, IgE

Source

Open in PubMed Open full text

Identifiers

PMID: 22583069
DOI: 10.1111/j.1398-9995.2012.02833.x
PMCID: PMC3401908

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.PMID 22583069Read ↗

Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.Semantic proximity Read ↗

Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.Semantic proximity Read ↗

Recent advances in the understanding and therapeutic management of mastocytosisSemantic proximity Read ↗

<i>KIT</i> and MastocytosisSemantic proximity Read ↗

Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and TreatmentSemantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Molecular basis of mast cell disease.Semantic proximity Read ↗

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatmentSemantic proximity Read ↗

Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.Semantic proximity Read ↗

Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.Semantic proximity Read ↗

How I treat patients with advanced systemic mastocytosis.Semantic proximity Read ↗

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.